NanoViricides Inc. (NNVC)

[arvitar]

In this "private" email from Seymour to a select group of investors, Seymour claims he has only one "drug", which would mean in regular English that he has only one candidate.

Of course, that wouldn't be inconsistent with their claim that "all candidates performed equally well" if there is just one candidate. Just misleading. (I added emphasis to key points):

3/12/2017 12:32:07 PM An email from Dr Seymour




Thanks for that nice summary of the various herpes viruses


One thing that I keep repeating but no one seems to understand:


We have one core drug that works for HSV-1, 2 and 3 (shingles)


Although we’ve only tested the drug against the first three, I suspect that it will work against ALL strains of the herpes virus (including Epstein-Barr and Cytomegalic virus) though we haven’t tested it against the last two strains


The drug will come in many different forms. A lotion, a topical cream for shingles, an ointment for cold sores and genital infections, a liquid for injection (cytomegalic virus infections in post-transplant patients and newborns as well as certain other forms of herpes infection) and a slightly denser version for a topical application that will stay on the cornea for herpes keratitis.


We make each form of the drug from scratch but the underlying drug, regardless of its final form, is the same


Have I made all of that clear in the past?







Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange